Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Feb 15;22(4):790-2.
doi: 10.1158/1078-0432.CCR-15-2514. Epub 2015 Dec 15.

Profiling Non-Small Cell Lung Cancer: From Tumor to Blood

Dana W Y Tsui  1 , Michael F Berger  2
Affiliations
Comment

Profiling Non-Small Cell Lung Cancer: From Tumor to Blood

Dana W Y Tsui et al. Clin Cancer Res. .

Abstract

Circulating cell-free tumor DNA has shown great promise for noninvasive genomic profiling to guide the administration of targeted therapies in non-small cell lung cancer. With advancements in molecular technology, it is now possible to interrogate multiple clinically actionable genetic drivers in the blood with a single assay.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: D.W.Y. Tsui reports receiving speakers bureau honoraria from AstraZeneca and was a consultant/advisory board member for Inivata at the time this commentary was written. M.F. Berger is a consultant/advisory board member for Cancer Genetics and Sequenom. No other potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1
Longitudinal profiling of cell-free DNA to detect driver mutations in non-small cell lung cancer before, during, and after treatment. Relevant driver mutations recurrently observed at diagnosis and at resistance are shown in the two pie charts. Changes in the relative representation of different clonal populations of cells (blue, red, green) are reflected in the levels of cell-free DNA in the plasma.
See this image and copyright information in PMC

Comment on

References

    1. Paweletz CP, Sacher AG, Raymond CK, Alden RS, O’Connell A, Mach SL, et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin Cancer Res. 2015 Oct 12; [Epub ahead of print] - PMC - PubMed
    1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18(3):349–51. - PubMed
    1. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole T, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–53. - PMC - PubMed
    1. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21(14):3196–203. - PubMed
    1. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res. 2006;12(13):3915–21. - PubMed

Publication types

MeSH terms